Litigation Details for Amgen Inc. v. MSN Laboratories Private Limited (D. Del. 2021)
✉ Email this page to a colleague
Amgen Inc. v. MSN Laboratories Private Limited (D. Del. 2021)
| Docket | ⤷ Sign Up | Date Filed | 2021-05-19 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | |
| Jury Demand | None | Referred To | |
| Patents | 10,344,765; 8,377,880; 8,999,932; 9,278,995; 9,701,712; 9,820,938 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Amgen Inc. v. MSN Laboratories Private Limited
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Biologic Drugs cited in Amgen Inc. v. MSN Laboratories Private Limited
The biologic drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Amgen Inc. v. MSN Laboratories Private Limited (D. Del. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2021-05-19 | 1 | Complaint | the ’995 patent”), 9,701,712 (“the ’712 patent”), 9,820,938 (“the ’938 patent”), and 10,344,765 (“the ’…expiration of U.S. Patent Nos. 8,377,880 (“the ’880 patent”), 8,999,932 (“the ’932 patent”), 9,278,995 (“… 1. This is an action for patent infringement under the patent laws of the United States, Title… ’765 patent”) (collectively, “the Asserted Patents”). MSN notified Plaintiffs that it had submitted …for its infringement of the ’880 patent. 30. The ’932 patent, titled “Therapeutic Agents for | External link to document |
| 2021-05-19 | 4 | Patent/Trademark Report to Commissioner | B2; 9,278,995 B2; 9,701,712 B2; 9,820,938 B2; 10,344,765 B2. (nmg) 19 May 2021 PACER Document … Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,377,880 B2; … 19 May 2021 1:21-cv-00712 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
